Heather J Dalton1, James V Fiorica2, Robert P Edwards3, Ivor Benjamin4, Rodney P Rocconi5, Fernando O Recio6, John L Lovecchio7, Matthew O Burrell8, Mark S Shahin9, Edward C Grendys10, Dakun Wang11, Tianhua Wang12, Bradley J Monk13. 1. The University of Texas M. D. Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, U.S.A. 2. First Physicians Group Gynecologic Oncology, Sarasota, FL, U.S.A. 3. University of Pittsburgh, Department of Obstetrics, Gynecology & Reproductive Sciences, Pittsburgh, PA, USA. 4. Arizona Center for Cancer Care, Gynecologic Oncology, Phoenix, AZ, U.S.A. 5. University of South Alabama Mitchell Cancer Institute, Gynecologic Oncology, Mobile, AL, U.S.A. 6. Florida Atlantic University, Obstetrics and Gynecology, Boca Raton, FL, U.S.A. 7. North Shore-LIJ Medical Group, Division of Gynecologic Oncology, Manhasset, NY, U.S.A. 8. Georgia Gynecology Oncology, Atlanta, GA, U.S.A. 9. Abington Memorial Hospital, Hanjani Institute for Gynecologic Oncology, Department of OB/GYN, Reproductive Sciences, Abington, PA, U.S.A. 10. Fort Myers Obstetricians & Gynecologists, Fort Myers, FL, U.S.A. 11. Precision Therapeutics, Department of Biology R & D, Pittsburgh, PA, U.S.A. dwang@ptilabs.com. 12. Precision Therapeutics, Department of Biology R & D, Pittsburgh, PA, U.S.A. 13. University of Arizona Cancer Center-Phoenix Creighton University School of Medicine at St. Joseph's, Department of Obstetrics and Gynecology, Phoenix, AZ, U.S.A.
Abstract
BACKGROUND/AIM: An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors. PATIENTS AND METHODS: RESULTS from metachronous tumors were examined in 242 patients. Changes in in vitro chemoresponse, measured by the area under the dose response curve (AUC) between paired tumors were assessed. RESULTS: A significant increase in AUC was identified in most first-line therapies over time. No significant difference was observed in most recurrent therapies. When the elapsed time between occurrences was <17 months, no difference was observed for any recurrent therapies, and half of first-line therapies exhibited significant increases in AUC. When ≥17 months, all 7 therapies showed significant increases. CONCLUSION: These results suggest an increase in chemoresistance over time, which is more pronounced for first-line therapies. This is consistent with clinical observations and suggests the biologic concordance between assay results and response to chemotherapy. Copyright
BACKGROUND/AIM: An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors. PATIENTS AND METHODS: RESULTS from metachronous tumors were examined in 242 patients. Changes in in vitro chemoresponse, measured by the area under the dose response curve (AUC) between paired tumors were assessed. RESULTS: A significant increase in AUC was identified in most first-line therapies over time. No significant difference was observed in most recurrent therapies. When the elapsed time between occurrences was <17 months, no difference was observed for any recurrent therapies, and half of first-line therapies exhibited significant increases in AUC. When ≥17 months, all 7 therapies showed significant increases. CONCLUSION: These results suggest an increase in chemoresistance over time, which is more pronounced for first-line therapies. This is consistent with clinical observations and suggests the biologic concordance between assay results and response to chemotherapy. Copyright